Lupin Gets FDA Tentative Approval for Sugammadex Injection

Lupin received tentative U.S. FDA approval for Sugammadex Injection (200 mg/2 mL and 500 mg/5 mL) ANDA on March 31, 2026.
The product is bioequivalent to Merck's Bridion® Injection, used for reversing neuromuscular blockade in adults and pediatric patients aged 2+.
Disclosure filed under SEBI LODR Regulation 30; Lupin operates across 100+ markets with 15 manufacturing sites globally.